SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM6-K
REPORT OF A FOREIGN ISSUER
PURSUANT TO RULE13A-16 OR15D-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For October 10, 2019
Commission File Number1-38455
MorphoSys AG
Semmelweisstrasse 7
82152 Planegg
Germany
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form20-F or Form40-F.
Form20-F ☒ Form40-F ☐
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule12g3-2(b):
Notification of managers`transactions according to article 19 MAR
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name | Dr. Jean-Paul Kress | ||||
2 | Reason for the notification | |||||
a) | Position/status | Member of the managing body | ||||
b) | Initial notification/Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | MorphoSys AG | ||||
b) | LEI | 529900493806K77LRE72 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument. type of instrument Identification code | Shares of MorphoSys AG, ISIN DE0006632003 | ||||
b) | Nature of the transaction | Acceptance of 57,078 stock options to subscribe for up to 2 shares each within the compensation as a Management Board Member (Stock-Option-Program 2019) | ||||
c) | Price(s) and volume(s) | Price | Volume | |||
Not quantifiable | Not quantifiable | |||||
d) | Aggregated information
• Aggregated volume
• Price | |||||
e) | Date of the transaction | 2019-10-07; UTC+2 | ||||
f) | Place of the transaction | Outside a trading venue |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
MORPHOSYS AG (Registrant) | ||||||
Date: October 10, 2019 | By: | /s/ Dr. Sarah Fakih | ||||
Name: | Dr. Sarah Fakih | |||||
Title: | Vice President | Head of Corporate Communications & IR | |||||
By: | /s/ Nicola Thomas | |||||
Name: | Nicola Thomas | |||||
Title: | Specialist Corporate Communications and Investor Relations |